Once monthly, golimumab is a cost-effective treatment alternative for patients with active PsA. With its patient-focussed attributes, golimumab is likely to offer additional choice in PsA treatment. </AbstractSection> Copyright Springer-Verlag 2012

In trial-based cost-effectiveness analysis baseline mean utility values are invariably imbalanced between treatment arms. A patient's baseline utility is likely to be highly correlated with their quality-adjusted life-years (QALYs) over the follow-up period, not least because it typically...

During recent discussions, it has been argued that stratified cost-effectiveness analysis has a key role in reimbursement decision‐making and value‐based pricing (VBP). It has previously been shown that when manufacturers are price‐takers, reimbursement decisions made in reference to...